2024
Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis
Ilagan-Ying Y, Gordon K, Tate J, Lim J, Torgersen J, Re V, Justice A, Taddei T. Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open 2024, 7: e2443608. PMID: 39504020, PMCID: PMC11541635, DOI: 10.1001/jamanetworkopen.2024.43608.Peer-Reviewed Original ResearchConceptsClassification of DiseasesBody mass indexRisk scoreNinth Revision and International Statistical Classification of DiseasesMass indexAlcohol useInternational Statistical Classification of DiseasesStatistical Classification of DiseasesElectronic health recordsNon-Hispanic blacksInternational Classification of DiseasesNon-Hispanic whitesClinical Modification diagnosisHepatocellular carcinoma risk scoreRisk of hepatocellular carcinomaCox proportional hazards regression modelsValidation sampleHigh-risk individualsProportional hazards regression modelsHCC risk factorsFIB-4Multivariate risk scoreHepatocellular carcinomaHazards regression modelsViral hepatitisScreening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosis
2023
The role of routine biopsy of the background liver in the management of hepatocellular carcinoma
Lee S, Ahmed M, Taddei T, Jain D. The role of routine biopsy of the background liver in the management of hepatocellular carcinoma. Human Pathology 2023, 138: 18-23. PMID: 37236406, DOI: 10.1016/j.humpath.2023.05.009.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyCarcinoma, HepatocellularFemaleHumansLiver CirrhosisLiver NeoplasmsMaleMiddle AgedConceptsLiver biopsyEarly HCC stagesHepatocellular carcinoma managementLarge university hospitalSeparate biopsiesCirrhosis statusClinical characteristicsClinical suspicionMedian ageEarly diseasePathology databaseRoutine biopsyHCC stageBiopsy resultsHCC patientsParenchymal findingsUniversity HospitalBackground liverHepatocellular carcinomaNontumoral liverHCC biopsiesBiopsyPatientsCirrhosisLiverMultidisciplinary teams, efficient communication, procedure services, and telehealth improve cirrhosis care: A qualitative study
Serper M, Agha A, Garren P, Taddei T, Kaplan D, Groeneveld P, Werner R, Shea J. Multidisciplinary teams, efficient communication, procedure services, and telehealth improve cirrhosis care: A qualitative study. Hepatology Communications 2023, 7: e0157. PMID: 37219845, PMCID: PMC10208700, DOI: 10.1097/hc9.0000000000000157.Peer-Reviewed Original ResearchConceptsVeterans Affairs Medical CenterCirrhosis careMedical CenterSpecialty Care Access Network-ExtensionMultidisciplinary teamCommunity Health care OutcomesManagement of complicationsPatients' social needsSame-day accessHealth care outcomesHigh-quality careComplex patient casesStaff discomfortPhysical examinationPrimary careCare coordinationPatient forgetfulnessCancer specialistsHepatology careClinicians' perceptionsPerson careTelehealth useTimely careTelehealth uptakeCare outcomesUrsodeoxycholic acid is associated with a reduction in SARS‐CoV‐2 infection and reduced severity of COVID‐19 in patients with cirrhosis
John B, Bastaich D, Webb G, Brevini T, Moon A, Ferreira R, Chin A, Kaplan D, Taddei T, Serper M, Mahmud N, Deng Y, Chao H, Sampaziotis F, Dahman B. Ursodeoxycholic acid is associated with a reduction in SARS‐CoV‐2 infection and reduced severity of COVID‐19 in patients with cirrhosis. Journal Of Internal Medicine 2023, 293: 636-647. PMID: 37018129, DOI: 10.1111/joim.13630.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19HumansLiver CirrhosisLiver Cirrhosis, BiliaryRetrospective StudiesSARS-CoV-2Ursodeoxycholic AcidConceptsSARS-CoV-2 infectionCritical COVID-19Ursodeoxycholic acidPropensity scoreCOVID-19Severe acute respiratory syndrome coronavirus 2Farnesoid X receptor activityAcute respiratory syndrome coronavirus 2Human lungRespiratory syndrome coronavirus 2COVID-19-related deathsRetrospective cohort studyModerate COVID-19Symptomatic COVID-19Multivariable logistic regressionLarge national cohortSyndrome coronavirus 2Coronavirus disease 2019Angiotensin-converting enzymePotential novel targetUDCA useClinical characteristicsCohort studyVaccination statusCoronavirus 2The association between mental illness and all-cause mortality in patients with cirrhosis: a Veterans Affairs retrospective cohort study
Shaffer L, Kaplan D, Taddei T, Mahmud N. The association between mental illness and all-cause mortality in patients with cirrhosis: a Veterans Affairs retrospective cohort study. Hepatology Communications 2023, 7: e0129. PMID: 36996031, PMCID: PMC10069831, DOI: 10.1097/hc9.0000000000000129.Peer-Reviewed Original ResearchConceptsMental health diagnosesAUD/SUDCause mortalityMental health visitsRetrospective cohort studyCohort studyHealth diagnosisHealth visitsSUD diagnosisMental illnessMental health clinic visitsMental health-related diagnosisOutpatient mental health visitsOutpatient mental health careVeterans Health AdministrationHealth-related careHealth-related diagnosesClinical practice changesHealth clinic visitsMental health careClinic visitsClinic utilizationCox regressionPsychiatric comorbiditySubgroup analysisMedications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan D. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatology Communications 2023, 7: e0093. PMID: 36972386, PMCID: PMC10043587, DOI: 10.1097/hc9.0000000000000093.Peer-Reviewed Original ResearchMeSH KeywordsAcamprosateAlcohol DeterrentsAlcoholismHumansLiver CirrhosisLiver Cirrhosis, AlcoholicNaltrexoneRetrospective StudiesConceptsAlcohol-associated cirrhosisAlcohol use disorderUse disordersCause mortalityImproved survivalPropensity scoreInpatient diagnosis codesRetrospective cohort studyCox regression analysisActive alcohol useCirrhosis decompensationCohort studyConcurrent diagnosisLiver diseasePotential confoundersDiagnosis codesVeteran outcomesCirrhosis diagnosisStrong negative predictorCirrhosisPatientsHazardous drinkingAlcohol use behaviorsCosts AssociatedAlcohol use
2022
Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study
Serper M, Kaplan DE, Taddei TH, Tapper EB, Cohen JB, Mahmud N. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology 2022, 77: 489-500. PMID: 35984731, PMCID: PMC9877112, DOI: 10.1002/hep.32737.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsCarvedilolCohort StudiesHepatitis CHumansLiver CirrhosisRetrospective StudiesViremiaConceptsNonselective beta blockersSelective beta blockersLiver-related mortalityHepatic decompensationBeta blockersCTP classPlatelet countSubgroup analysisLiver disease etiologyLower hazardNational cohort studyNew-user designInverse probability treatmentRoutine clinical settingPrior decompensationViremia statusChild-TurcotteHCV viremiaClinical confoundersComposite outcomeCohort studyPrimary outcomeActive comparatorNational cohortDecompensationHolistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentThird dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis
John BV, Ferreira RD, Doshi A, Kaplan DE, Taddei TH, Spector SA, Paulus E, Deng Y, Bastaich D, Dahman B. Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. Journal Of Hepatology 2022, 77: 1349-1358. PMID: 36181987, PMCID: PMC9519143, DOI: 10.1016/j.jhep.2022.07.036.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinesCritical COVID-19COVID-19-related deathsThird doseMRNA vaccinesCOVID-19Propensity-matched control groupRetrospective cohort studyModerate COVID-19Symptomatic COVID-19Veterans Health AdministrationBNT-162b2BNT162b2 mRNAModerna mRNACohort studyImmune dysregulationCirrhosisSimilar riskGeneral populationMagnitude of reductionPatientsControl groupHealth AdministrationVaccineAbstractTextType of Infection Is Associated with Prognosis in Acute-on-Chronic Liver Failure: A National Veterans Health Administration Study
Mahmud N, Reddy KR, Taddei TH, Kaplan DE. Type of Infection Is Associated with Prognosis in Acute-on-Chronic Liver Failure: A National Veterans Health Administration Study. Digestive Diseases And Sciences 2022, 68: 1632-1640. PMID: 36083379, PMCID: PMC9995592, DOI: 10.1007/s10620-022-07680-9.Peer-Reviewed Original ResearchMeSH KeywordsAcute-On-Chronic Liver FailureHumansLiver CirrhosisPeritonitisPrognosisRetrospective StudiesVeterans HealthConceptsSpontaneous bacterial peritonitisChronic liver failureShort-term mortalityLiver failureHigh short-term mortalityACLF grade 3Retrospective cohort studyUrinary tract infectionMultivariable logistic regressionVeterans Health AdministrationType of infectionInverse probability treatmentLarge national databaseSource of infectionACLF gradeMSK infectionsCohort studyTract infectionsBacterial peritonitisMusculoskeletal infectionsFrequent precipitantInfectious sourceGrade 3Relative oddsHealth AdministrationPatterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic
Serper M, Tapper EB, Kaplan DE, Taddei TH, Mahmud N. Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic. The American Journal Of Gastroenterology 2022, 118: 294-303. PMID: 36114778, PMCID: PMC9898115, DOI: 10.14309/ajg.0000000000002011.Peer-Reviewed Original ResearchConceptsOutpatient primary care providerHepatocellular carcinoma surveillancePrimary care providersHCC surveillanceCare providersHCC surveillance ratesGastroenterology/hepatologyFacility-level variablesCirrhosis cohortPatient demographicsClinical factorsTotal cohortCare utilizationNational cohortOutpatient utilizationSpecialty careInpatient careMultivariable modelPercentage of timePopulation-based approachSurveillance ratesAppointment ratesAdjusted modelVisit ratesCoronavirus diseaseCOVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis
John B, Bastaich D, Ferreira R, Doshi A, Taddei T, Kaplan D, Spector S, Deng Y, Dahman B. COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis. Gut 2022, 72: 1800-1802. PMID: 36562753, DOI: 10.1136/gutjnl-2022-327799.Peer-Reviewed Original ResearchComparison of infection‐induced and vaccine‐induced immunity against COVID‐19 in patients with cirrhosis
John BV, Doshi A, Ferreira RD, Taddei TH, Kaplan DE, Spector SA, Deng Y, Bastaich D, Dahman B. Comparison of infection‐induced and vaccine‐induced immunity against COVID‐19 in patients with cirrhosis. Hepatology 2022, 77: 186-196. PMID: 35712794, DOI: 10.1002/hep.32619.Peer-Reviewed Original ResearchConceptsPositive SARS-CoV-2 polymerase chain reactionVaccine-induced immunitySARS-CoV-2 infectionInfection-induced immunityImmunity groupsReduced oddsSARS-CoV-2 polymerase chain reactionCOVID-19Retrospective cohort studyCritical COVID-19Multivariable logistic regressionSARS-CoV-2Unvaccinated participantsUnvaccinated patientsFull vaccinationCohort studyCOVID-19 variantsCommunity prevalencePrevious infectionMRNA vaccinesPolymerase chain reactionUS veteransTreatment weightingCirrhosisPropensity scorePostvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis
John BV, Deng Y, Schwartz KB, Taddei TH, Kaplan DE, Martin P, Chao H, Dahman B. Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology 2022, 76: 126-138. PMID: 35023206, PMCID: PMC9015228, DOI: 10.1002/hep.32337.Peer-Reviewed Original ResearchMeSH KeywordsBNT162 VaccineCOVID-19COVID-19 VaccinesHumansLiver CirrhosisRetrospective StudiesRNA, MessengerConceptsCOVID-19 infectionCOVID-19Breakthrough COVID-19 infectionsBreakthrough COVID-19Propensity-matched cohortRetrospective cohort studyCOVID-19 patientsPfizer BNT162b2Unvaccinated participantsFull vaccinationCohort studyFirst dosePartial vaccinationMultivariable analysisSecond doseUS veteransCirrhosisReduced riskVaccine availabilityPatientsVaccinationVaccineInfectionMortalityDoseEffectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis
John BV, Barritt A, Moon A, Taddei TH, Kaplan DE, Dahman B, , Doshi A, Deng Y, Mansour N, Ioannou G, Martin P, Chao H. Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis. Clinical Gastroenterology And Hepatology 2022, 20: 2405-2408.e3. PMID: 35716904, PMCID: PMC9212810, DOI: 10.1016/j.cgh.2022.05.038.Peer-Reviewed Original ResearchThe Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study
Mahmud N, Serper M, Taddei TH, Kaplan DE. The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Gastroenterology 2022, 163: 257-269.e6. PMID: 35398042, PMCID: PMC10020994, DOI: 10.1053/j.gastro.2022.03.052.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesGastrointestinal HemorrhageHumansLiver CirrhosisProton Pump InhibitorsRetrospective StudiesRisk FactorsVeteransConceptsLiver-related mortalityPPI exposureGastrointestinal bleedingCause mortalityProton pump inhibitor exposurePrior gastrointestinal bleedingTime-updated variablesCause-specific mortality analysesLarge national cohortVeterans Health AdministrationRisk of infectionCardiovascular comorbiditiesPPI useCohort studyStatin exposureCox regressionRetrospective studyAdverse outcomesAppropriate indicationsNational cohortInhibitor exposureSevere infectionsCirrhosis diagnosisAdditional adjustmentAdjusted modelReply to: “Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?”
Torgersen J, Taddei TH, Lo Re V. Reply to: “Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?”. Journal Of Hepatology 2022, 77: 258-259. PMID: 35283213, DOI: 10.1016/j.jhep.2022.02.025.Peer-Reviewed Original ResearchStatin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort
Mahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal Of Hepatology 2022, 76: 1100-1108. PMID: 35066085, PMCID: PMC9018495, DOI: 10.1016/j.jhep.2021.12.034.Peer-Reviewed Original ResearchConceptsChronic liver failureStatin exposureLiver failureStatin useCohort studyChronic liver failure developmentInverse probability treatment weightingProportional hazards regression modelsDoses of statinsVeterans Affairs cohortRetrospective cohort studyChronic liver diseaseHazards regression modelsLarge national cohortVeterans Health AdministrationNumerous beneficial effectsMarginal structural modelsMedian followStatin therapyLiver diseaseNational cohortACLFTreatment weightingCirrhosisPatients
2021
Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis
John BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D, Labrada M, Baracco G, Dahman B. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Internal Medicine 2021, 181: 1306-1314. PMID: 34254978, PMCID: PMC8278308, DOI: 10.1001/jamainternmed.2021.4325.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionCOVID-19-related hospitalizationBNT162b2 mRNAFirst doseCohort studySecond doseMRNA vaccinesClinical trialsControl groupPropensity-matched control groupPhase 3 clinical trialsCOVID-19 mRNA vaccinesAssociation of vaccinationRetrospective cohort studyUS veteran populationAssociation of receiptVeterans Health AdministrationCoronavirus disease 2019COVID-19 hospitalizationMRNA vaccine administrationCOVID-19Vaccine recipientsImmune dysregulationModerna mRNAMedian age